Trial Profile

Retrospective Observational Study on Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections - DALBADIA Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalbavancin (Primary)
Indications Gram-positive infections
Focus Therapeutic Use
Acronyms DALBADIA
Sponsors Angelini Pharmaceuticals

Most Recent Events

19 Sep 2022 Status changed from recruiting to completed.
09 Mar 2022 Planned End Date changed from 31 Jan 2022 to 30 Jun 2022.
09 Mar 2022 Planned primary completion date changed from 31 Jan 2022 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com